Lufotrelvir

Lufotrelvir is an antiviral drug that is currently under investigation for the treatment of COVID-19. It is a prodrug of remdesivir, which means it is metabolically converted into the active drug remdesivir in the body.

Mechanism of Action

Lufotrelvir works by inhibiting the RNA-dependent RNA polymerase (RdRp) of the SARS-CoV-2 virus. RdRp is an essential enzyme for the replication of the virus. By inhibiting this enzyme, lufotrelvir prevents the virus from multiplying in the body.

Clinical Trials

Lufotrelvir is currently being tested in clinical trials for the treatment of COVID-19. Preliminary results have shown promise, but more research is needed to confirm its efficacy and safety.

Side Effects

As with any medication, lufotrelvir may cause side effects. These can include nausea, vomiting, and diarrhea. More serious side effects can include liver damage and allergic reactions.

Contraindications

Lufotrelvir should not be used in patients with a known allergy to remdesivir or any of its components. It should also be used with caution in patients with liver disease.

See Also

• Remdesivir
• Antiviral drug
• COVID-19 treatment

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian